Prostate Cancer Imaging

前列腺癌是美国男性中最常见的癌症，但目前还没有令人满意的成像方法来定位前列腺癌。一种成功定位前列腺癌的成像方法可能有助于诊断、指导治疗和监测复发。我们已经建立了一个由泌尿科医生、放射肿瘤学家、诊断放射科医生、MR工程师和物理学家组成的多学科团队，以开发3 Tesla MRI前列腺成像的先进方法。用直肠内线圈扫描患者，并进行高分辨率T2加权MRI、MR波谱和动态对比增强MRI。结果被合成为多参数图像，然后与活检或解剖标本进行比较。Michael Emmert-Buck博士的实验室对这种材料进行了研究，以确定潜在的新型细胞表面标志物。这些标记物可能在未来用于开发下一代前列腺癌靶向成像。这项研究的一个独特之处在于，癌症相对于腺体其余部分的空间完整性得以保持，使得细胞表面标记物数据与MRI在空间上相关。此外，我们还参与MR引导的前列腺活检。在MIP实验室，我们正在开发基于Emmert Buck博士的发现的下一代分子靶向成像剂。使用人异种移植肿瘤模型来测试靶向探针（例如111 In标记的PSMA抗体、Cy5.5标记的PSMA适体等）的功效。

Prostate cancer is the most commonly diagnosed cancer in American men yet there are no satisfactory imaging methods for localizing prostate cancer within the gland. An imaging method that successfully localized prostate cancers could be useful for diagnosis, directing therapy and monitoring for recurrence. We have developed a multidisciplinary team of urologists, radiation oncologists, diagnostic radiologists, MR engineers and physicists to develop advanced methods of prostate imaging with MRI at 3Tesla. Patients are scanned with an endorectal coil and high resolution T2 weighted MRI, MR spectroscopy and dynamic contrast enhanced MRI are performed. The results are synthesized to a multiparametric image that is then compared with the biopsy or anatomic specimen. This material, in turn is investigated by the laboratory of Dr. Michael Emmert-Buck to identify potential novel cell surface markers. These markers may be used in the future to develop the next generation of prostate cancer targeted imaging. A unique aspect of this research is that spatial integrity of the cancer with respect to the rest of the gland is maintained so that the cell surface marker data is spatially correlated with MRI. Additionally, we participate in MR guided biopsies of the prostate. In the MIP laboratory we are developing the next generation of molecularly targeted imaging agents based on the findings of Dr. Emmert Buck. Human xenograft tumor models are used to test the efficacy of targed probes (e.g. 111In labeled PSMA antibody, Cy5.5 labeled PSMA aptamer among others).